Stockreport

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Alpha Tau Medical Ltd. - Ordinary Shares  (DRTS) 
PDF - Initial module submission marks an important milestone in the pre-market approval process -  - Flexible modular submission framework granted to Alpha Tau by the FDA a [Read more]